Showing results (31-40 of 322) with videos related to
Sort By:
Pageof 33
Leukemia|February 15, 2020
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approachesNina Shah, Ajai Chari, Emma Scott, et al.The Lancet. Haematology|May 28, 2021
CAR T-cell therapy for multiple myeloma: state of the art and prospectsNiels W C J van de Donk, Saad Z Usmani, Kwee YongJournal of Gastrointestinal Cancer|December 10, 2008
Duodenal MALT lymphoma presenting with obstructive jaundice: report of a case and review of the literatureSaad Z Usmani, Li Ding, Ahmad H Abu-Rashed, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 28, 2018
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvementJustin R Arnall, Saad Z Usmani, Hawawu Adamu, et al.Leukemia & Lymphoma|July 7, 2020
Management of newly diagnosed transplant ineligible multiple myelomaShebli Atrash, Manisha Bhutani, Barry Paul, et al.Haematologica|August 21, 2025
Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United StatesAishwarya Anuraj, Divya Rath, Andriy Derkach, et al.Blood Cancer Discovery|August 13, 2021
Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myelomaNiels W C J van de Donk, Maria Themeli, Saad Z UsmaniExpert Review of Hematology|September 21, 2021
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weeklyXavier Leleu, Ajai Chari, Shambavi Richard, et al.Expert Review of Hematology|July 14, 2020
An evaluation of subcutaneous daratumumab for the treatment of multiple myelomaBarry Paul, Shebli Atrash, Manisha Bhutani, et al.American Journal of Hematology|May 6, 2017
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparisonSaad Z Usmani, Joris Diels, Tetsuro Ito, et al.Pageof 33